Previous 10 | Next 10 |
Investment Thesis Guardant Health, Inc. ( GH ), a company providing cancer screening tests, has seen its top-line rising exponentially in recent quarters amid growing margins. The share price has surged ~17% higher since the recent upward guidance to 2019 outlook. The growing volumes and p...
Image source: The Motley Fool. Guardant Health Inc (NASDAQ: GH) Q3 2019 Earnings Call Nov 7, 2019 , 4:30 p.m. ET Operator Continue reading
Now is a great time to have biotech stocks in your portfolio. While biotech investing can be scary, because the small-cap companies are often unprofitable research-and-development labs, this is also where a lot of the cutting-edge science is happening. Let's see how Mirati Therapeutics (NA...
Guardant Health Inc (GH) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Carrie Mendivil – Investor Relations Helmy Eltoukhy – Co-Founder and Chief Executive Officers AmirAli Talasaz – President and Co-Founder Derek Bertocc...
Shares of Guardant Health (NASDAQ: GH) jumped 12% on Friday following the company's announcement of its third-quarter results after the market closed on Thursday. Guardant Health reported that its revenue skyrocketed 181% year over year in Q3 to $60.8 million. The company posted a net loss o...
Guardant Health (NASDAQ: GH ) is up 11% premarket on light volume following its Q3 results released after the close yesterday. Highlights: More news on: Guardant Health, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Guardant Health (NASDAQ: GH ): Q3 GAAP EPS of -$0.14 beats by $0.23 . Revenue of $60.8M (+180.3% Y/Y) beats by $15.4M . Shares +3.7% . Press Release More news on: Guardant Health, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news,
REDWOOD CITY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for...
Guardant Health (NASDAQ: GH ) is a $6 billion+ market capitalization precision oncology testing company that is developing some exciting new technology in the cancer space. The company announced the closing of its initial public offering on October 9 of last year, raising just over $270 millio...
Guardant Health (NASDAQ: GH ) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$0.37 (+80.9% Y/Y) and the consensus Revenue Estimate is $45.4M (+109.3% Y/Y). Over the last 3 months, EPS estimates have seen 4 upw...
News, Short Squeeze, Breakout and More Instantly...
Guardant’s Impact, Innovation, Ambition, and Success Contributed to the Recognition Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making...
Studies demonstrate benefits of liquid biopsy and real-world data in targeted therapy selection and therapeutic outcomes in advanced breast cancer Interim data from PICI’s RADIOHEAD study using Guardant Infinity™ platform show correlation between epigenomic biomarkers and pa...
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moder...